Published in Volume
119, Issue 1 (January 5, 2009)
J Clin Invest. 2009;119(1):13–15.
doi:10.1172/JCI38096.
Copyright © 2009, American Society for Clinical
Investigation
Commentary
CD4+ T cells mediate cytotoxicity in neurodegenerative
diseases
Stanley H. Appel
Department of Neurology, Methodist Neurological Institute, Houston,
Texas, USA.
Address correspondence to: Stanley H. Appel, Department of Neurology, Methodist
Neurological Institute, 6560 Fannin St., #802, Houston, Texas 77030, USA. Phone:
(713) 441-3765; Fax: (713) 793-7271; E-mail: sappel@tmhs.org.
First published December 22, 2008
Neuroinflammation, characterized by activated microglia and infiltrating T cells, is
a prominent pathological feature in neurodegenerative diseases. However, whether this
inflammation contributes to neuronal injury or is a late consequence of neuronal
injury is unclear. In this issue of the JCI, Brochard et al. report
that CD4+ T cells are cytotoxic in a mouse model of Parkinson disease (PD)
(see the related article beginning on page 182). Specifically, invading T lymphocytes
contributed to neuronal cell death via the Fas/FasL pathway. The results implicate
the adaptive immune system in the pathogenesis of Parkinson neurodegeneration and
provide a meaningful rationale for immune-based therapies for PD.
See the related article beginning on page 182.
Neuroinflammation in Parkinson disease
Parkinson disease (PD) is a motor system disorder, which is characterized by tremor,
rigidity, slowed movements, and impaired balance and coordination and results from the
loss of dopamine-producing cells in the brain. The nigrostriatal pathway — a
neural pathway connecting the substantia nigra with the striatum — is one of
four major dopamine signaling pathways in the brain and is prominently involved in
controlling movement. In PD, the nigrostriatal pathway as well as dopaminergic and
nondopaminergic neurons are compromised, and this is accompanied by inflammatory changes
in microglia (the innate immune cells of the central nervous system) and infiltration of
T lymphocytes (cells of the adaptive immune system). It has long been thought that
microglial and T cell infiltration are not primary events in the pathogenesis of
neurodegeneration but are instead responses to neuronal injury. However, recent studies
(discussed below) support an alternative point of view and provide compelling evidence
that both activated microglia and T lymphocytes make a significant contribution to
neurodegeneration, at the very least by amplifying and exacerbating an ongoing
inflammatory process and by triggering extensive neuronal degeneration to develop from a
small population of stressed dopaminergic neurons.
The role of microglia in dopaminergic cytotoxicity
Much attention has focused on microglia as one of the mediators of the inflammatory
response leading to dopaminergic neuronal injury. Microglia are similar to macrophages
and are capable of exhibiting either an M1 proinflammatory phenotype (following
activation with LPS), characterized by the secretion of proinflammatory cytokines, NO,
and superoxide, or an M2 antiinflammatory phenotype (following incubation with IL-4),
characterized by the secretion of neurotrophic factors such as IGF-1 and IL-10 (1). In vitro, LPS-induced microglial activation
triggers the release of proinflammatory factors, including NO,
H2O2, and superoxide, causing neurodegeneration of ventral
midbrain dopaminergic neurons (2). In vivo,
elevations of proinflammatory factors have been associated with degeneration of
dopaminergic neurons in PD (3), in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–intoxicated (MPTP-intoxicated)
patients (MPTP is a neurotoxin, the administration of which causes PD symptoms) (4), and in MPTP-induced animal models of PD (5). Further, blocking microglial activation with the
antibiotic minocycline in the MPTP-induced model of PD prevents dopaminergic
neurodegeneration (6).
α-Synuclein as a mediator of microglial activation
The question of what could activate microglia and in turn aggravate neuronal injury has
focused attention on the protein α-synuclein (α-Syn), which is
expressed predominantly in neurons and is particularly enriched at presynaptic
terminals. α-Syn accumulates in mutant forms (7) or as overexpressed wild-type protein (8) in familial PD and in nitrated and oxidized forms in cytosolic aggregates in
PD patients (9). Transgenic expression of human
α-Syn in mice renders dopaminergic neurons more vulnerable to LPS-induced
inflammation, which in turn leads to accumulation of insoluble α-Syn
aggregates in nigral neurons (10). In
dopaminergic neuronal cultures, dopaminergic neuron cytotoxicity is dependent on the
presence of α-Syn and is attenuated in the presence of inhibitors of NO and
superoxide released from microglia (10). Thus,
altered forms of α-Syn released from stressed neurons appear to participate
in a self-propagating cycle, in which microglia are activated, enhancing the release of
free radicals and proinflammatory cytokines and further amplifying dopaminergic
neurodegeneration.
T cells mediate cytotoxicity in the MPTP-induced mouse model of PD
Although microglia are clearly participants in the pathogenesis of nigral
neurodegeneration, the role of T cells has been heretofore less clear. The report by
Brochard et al. in this issue of the JCI (11) documents the presence of activated microglia and
CD4+ and CD8+ T cells in postmortem substantia nigra of PD
patients as well as in the MPTP-induced model of PD during the course of neuronal
degeneration. Following administration of MPTP, increased numbers of activated
microglial cells were noted prior to the appearance of CD3+ T cells and
concomitant with astrogliosis, suggesting the possible role of microglia in recruiting T
cells to the injured substantia nigra. When MPTP was administered to two different
strains of immunodeficient mice that lack mature T lymphocytes
(Tcrb–/– and
Rag1–/– mice), T cell
infiltration of the substantia nigra pars compacta was markedly reduced and dopaminergic
cell injury was attenuated. In the absence of T cells, dopaminergic neurodegeneration
was attenuated. Thus, T cells mediate neuronal cytotoxicity in the MPTP-induced murine
model of PD. CD4+ T cells are the population of T cells mediating the
cytotoxicity, since dopaminergic neuron survival following MPTP administration was
increased in Cd4–/– mice but not in
Cd8–/–
mice. The resistance to MPTP-induced neurodegeneration observed in
Rag1–/– mice could be reversed
when spleen cells from wild-type or
Ifng–/– mice, but not from mice
bearing mutant FasL, were passively transferred prior to MPTP administration. Thus, in
MPTP-mediated dopaminergic cell death, CD4+ T cells require the expression of
a functional proapoptotic FasL but not the inflammatory cytokine Ifn-γ.
Previous studies have shown that levels of IFN-γ are significantly elevated
in PD patients as well as in the MPTP-mediated mouse model of PD (12). In Ifng–/–
mice, MPTP-induced loss of substantia nigra pars compacta neurons was attenuated as was
microglial activation (12). The importance of
Ifn-γ would suggest the involvement of CD4+ Th1 cells, which can
secrete Ifn-γ and activate microglia (13). However, in the current study reported by Brochard et al. (11), the fact that the effect on MPTP-induced
neurodegeneration was the same irrespective of whether spleen cells were passively
transferred from wild-type or
Ifng–/– mice (11) suggests that Ifn-γ may not be required for T
cell–mediated dopaminergic cell death. Thus Th1 cells, which secrete
Ifn-γ, may not be the relevant subpopulation involved in the MPTP-mediated T
cell toxicity observed. The demonstration that expression of a functional FasL was
required for the CD4+ Th cell–mediated dopaminergic cell death
supports the involvement of CD4+ FasL+ T cell populations, which
could activate microglia to secrete proinflammatory factors (14). The recently described IL-17–secreting Th17
lymphocytes represent another proinflammatory T cell that could mediate CD4+
T cell–induced cytotoxicity. The main function of
IL-17–secreting T cells is to mediate inflammation, by stimulating
production of inflammatory cytokines such as TNF-α, IL-1β, and
IL-6 (15). Clearly, the identity of the T cells
responsible for the enhanced dopaminergic cytotoxicity cannot be definitively determined
until this issue is addressed by passive transfer of specific subpopulations of
CD4+ T cells. It is of interest that nitrated α-Syn may
participate in the T cell–mediated cytotoxicity, since transfer of T cells
from mice immunized with nitrotyrosine-modified α-Syn led to a robust
neuroinflammatory response, with accelerated dopaminergic cell loss (16). Collectively, the data suggest that
CD4+ T cells mediate cytotoxicity, by activating microglia to release free
radicals and proinflammatory cytokines and induce dopaminergic neurodegeneration.
However, a direct toxic effect of CD4+ T cells on substantia nigra
dopaminergic neurons cannot be excluded.
Neuroinflammation can be neuroprotective as well as cytotoxic
Marked microglial activation and lymphocytic infiltration are also present in patients
with the neurodegenerative disease amyotrophic lateral sclerosis (ALS) as well as in
transgenic mice overexpressing mutant Cu-Zn superoxide dismutase 1 (mSOD1), an animal
model of familial ALS (17). Surprisingly, T cells
were reported to be neuroprotective in this model, rather than cytotoxic as currently
reported in the MPTP-induced murine models of PD (11) (Figure 1). When mSOD1 mice were bred
with Rag2–/– mice lacking functional
T cells or with Cd4–/– mice lacking
CD4+ T cells, motor neuron disease was accelerated, accompanied by
increased mRNA levels of proinflammatory cytokines and NADPH oxidase 2 (NOX2), which is
responsible for generating superoxide (18).
Levels of trophic factors and glial glutamate transporters were also decreased. Bone
marrow transplants reconstituted mice with T cells, prolonged survival, and suppressed
cytotoxicity in conjunction with restoring expression of neuroprotective factors and
lessening the expression of NOX2. Thus, CD4+ T cells significantly influence
the neurodegenerative process in both the MPTP-induced murine model of PD and a
transgenic mouse model of familial ALS, mediating cytotoxicity in the former and
neuroprotection in the latter.
Conclusion
The development of immunotherapeutic approaches to the treatment of PD will depend on
determining which subpopulations of CD4+ T cells are responsible for
cytotoxicity and which of these may enhance neuroprotection. With the compelling
evidence now provided by Brochard and colleagues (11), that CD4+ T cells mediate cytotoxicity in the MPTP-induced mouse
model of PD, Th1 and Th17 cells become potential targets in efforts to minimize the
hostile neuronal microenvironment. IL-12 enhances expression of the transcription
factors STAT4 and T-bet, which regulate lineage commitment and development of
CD4+ Th cells from naive T cells. TGF-β, in addition to IL-6 or
IL-21, enhances expression of the transcription factor RORγt and promotes
development of Th17 from naive T cells, the expansion of which is enhanced by IL-1 and
IL-23 (19). Suppressing these differentiating
signals as well as the Th1 and/or Th17 cells themselves has now become a potentially
meaningful approach to immunotherapy for PD. An alternative approach might focus on
Tregs, which appear capable of regulating immune responses mediated by other T cell
subtypes, including Th17 cells. Therefore, increasing numbers of Tregs in order to
suppress proinflammatory T cells might also foster a more neuroprotective environment.
Most significantly, these and other immune-based strategies now have a cogent rationale,
given the demonstration that T cells themselves are orchestrating cytotoxic events in
the MPTP-induced mouse model of PD (11) and
possibly in human PD itself.
Acknowledgments
The author is supported by the Muscular Dystrophy Association and the NIH.
Footnotes
Conflict of interest: The author has declared that no conflict of
interest exists.
Nonstandard abbreviations used: ALS, amyotrophic lateral sclerosis;
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson disease;
α-Syn, α-synuclein.
Citation for this article:
J. Clin. Invest. 119:13–15 (2009). doi:10.1172/JCI38096.
See the related article beginning on page 182.
References
-
Mantovani, A. 2004. The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol. 25:677-686.
-
Le, W., et al. 2001. Microglial activation and dopaminergic cell injury: an in vitro model
relevant to Parkinson’s disease. J. Neurosci. 21:8447-8455.
-
McGeer, P.L., Itagi, S., Akiyama, H. 1988. Rate of cell death in parkinsonism indicates active neuropathological
process. Ann. Neurol. 24:574-576.
-
Langston, J.W., et al. 1999. Evidence of active nerve degeneration in the substantia nigra of
humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyidine exposure. Ann. Neurol. 46:598-605.
-
Liberatore, G., et al. 1999. Inducible nitric oxide synthase stimulates dopaminergic
neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1403-1409.
-
Wu, D.C., et al. 2002. Blockade of microglial activation is neuroprotective in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyidine mouse model of Parkinson disease. J. Neurosci. 22:1763-1771.
-
Polymeropoulos, M.H., et al. 1997. Mutation in the alpha-synuclein gene identified in families with
Parkinson’s disease. Science. 276:2045-2047.
-
Farrer, M.J., et al. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic
multiplications. Ann. Neurol. 55:174-179.
-
Martinez-Vicente, M. 2008. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118:777-788.
-
Gao, H.-M., et al. 2008. Neuroinflammation and oxidation/nitration of α-synuclein
linked to dopaminergic neurodegneration. J. Neurosci. 28:7687-7698.
-
Brochard, V., et al. 2009. Infiltration of CD4+ lymphocytes into the brain contributes
to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119:182-192.
-
Mount, M.P., et al. 2007. Involvement of interferon-gamma in microglia-mediated loss of
dopaminergic neurons. J. Neurosci. 27:3328-3337.
-
Mosmann, T.R., et al. 1986. Two types of murine helper T cell clone. 1. Definition according to
profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2357.
-
Park, D.R., et al. 2003. Fas(CD95) induces proinflammatory cytokine responses by human
monocytes and monocyte-derived macrophages. J. Immunol. 170:6209-6216.
-
Kebir, H., et al. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and
central nervous system inflammation. Nat. Med. 13:1173-1175.
-
Benner, E.J. 2008. Nitrated α-synuclein immunity accelerates degeneration of
nigral dopaminergic neurons. PLoS ONE. 3:e1376.
-
Henkel, J.S., Beers, D.R., Siklos, L., Appel, S.H. 2006. The chemokine MCP-1 and the dendritic and myeloid cells it attracts
are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31:427-437.
-
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Appel, S.H. 2008. CD4+ T cells support glial neuroprotection, slow disease progression,
and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 105:15558-15563.
-
Mills, K.H.G. 2008. Induction, function, and regulation of IL-17-producing T cells. Eur. J. Immunol. 38:2636-2649.